Magnetic Resonance Imaging Findings and Prostate‐Specific Antigen Density‐Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate
International Journal of Urology · 2026-11 · 33 (11)
DOI: 10.1111/iju.70694 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 05.11.2026. Verfasst von Taku Mitome und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, International Goodwill Hospital, Yokohama, Japan. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Prostatic Neoplasms, Prostate-Specific Antigen, Prostate. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate whether a separate preoperative prostate biopsy can be deferred using magnetic resonance imaging (MRI) and prostate‐specific antigen density (PSAD) in candidates for holmium laser enucleation of the prostate (HoLEP).
Methods
We retrospectively analyzed 625 patients who underwent HoLEP. In the high prostate‐specific antigen (PSA) cohort (≥ 4.0 ng/mL, n = 455), the diagnostic performance of PSAD was evaluated. In patients without a prior biopsy within 1 year who underwent preoperative MRI ( n = 126), candidates for biopsy deferral (MRI‐negative and PSAD < 0.20 ng/mL/mL, n = 95) were assessed. Clinically significant prostate cancer (csPCa) detection rates and histologically validated negative predictive values (NPVs) were determined using simultaneous peripheral zone (PZ) biopsy.
Results
Multivariable analysis identified PSAD ≥ 0.20 ng/mL/mL as an independent predictor of csPCa (odds ratio: 3.80, 95% confidence interval [CI]: 1.35–10.64, p = 0.011). In patients without a prior biopsy within 1 year ( n = 343), PSAD < 0.20 ng/mL/mL achieved a specificity of 85.9% and a biopsy deferral rate of 84.8%. Among 126 MRI‐evaluated patients, the combined criteria (MRI‐negative and PSAD < 0.20 ng/mL/mL) yielded a sensitivity of 83.3%, specificity of 78.3%, an NPV of 98.9% (94/95), and a biopsy deferral rate of 75.4% (95/126). The histologically validated NPV obtained via simultaneous PZ biopsy ( n = 77) was 98.7% (76/77).
Conclusions
Combining negative MRI and PSAD < 0.20 ng/mL/mL demonstrated a high NPV for csPCa and may allow the deferral of separate preoperative biopsies in selected patients with large‐volume benign prostatic hyperplasia (BPH).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, International Goodwill Hospital, Yokohama, Japan.
- Department of Urology, Yokohama City University Hospital, Yokohama, Kanagawa, Japan.
- Department of Urology, Kanagawa Prefectural Ashigarakami Hospital, Matsuda-machi, Kanagawa, Japan.
ORCID-Profile: Taku Mitome, Hibiki Hirose, Shinichi Takebe, Akitoshi Takizawa
Zitieren
APA
Mitome, T., Hirose, H., Demizu, N., Tokumoto, M., Takebe, S., Morikawa, T., Morinaga, R., Yoneyama, S., & Takizawa, A. (2026). Magnetic Resonance Imaging Findings and Prostate‐Specific Antigen Density‐Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate. International Journal of Urology, 33(11). https://doi.org/10.1111/iju.70694
Vancouver
Mitome T, Hirose H, Demizu N, Tokumoto M, Takebe S, Morikawa T, et al. Magnetic Resonance Imaging Findings and Prostate‐Specific Antigen Density‐Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate. International Journal of Urology. 2026;33(11). doi:10.1111/iju.70694
BibTeX
@article{Mitome2026,
author = {Mitome, Taku and Hirose, Hibiki and Demizu, Nanaho and Tokumoto, Mei and Takebe, Shinichi and Morikawa, Tomoharu and Morinaga, Ryota and Yoneyama, Shuko and Takizawa, Akitoshi},
title = {Magnetic Resonance Imaging Findings and Prostate‐Specific Antigen Density‐Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/iju.70694}
}
EUVIMED